Annexon Biosciences reveals positive data from ANX007 Phase 1b trial
Category: #health  By Mateen Dalal  Date: 2019-10-11
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Annexon Biosciences reveals positive data from ANX007 Phase 1b trial

Glaucoma is an eye condition in which fluid pressure builds up within the eye affecting optic nerves. If not treated, a Glaucoma patient might lose partial vision or even go blind. The disease mostly occurs in older adults and cannot be cured. However, it can be prevented if treated in the early stage.

Several pharma companies are now developing concrete therapy, in order to eradicate this disease. Annexon Biosciences recently made some strides by announcing positive results from the Phase 1b dose-ranging clinical study assesses ANX007, an anti-C1q antibody, in patients with Glaucoma.

For the record, ANX007 is an investigational monoclonal antibody Fab (antigen-binding fragment) created for intravitreal administration.

According to reliable sources, ANX007 showed well-tolerated results in full target inhibition and engagement of C1q in the eye for a minimum of four weeks, accompanying a single intravitreal treatment.

Speaking on the development, Jeffrey L. Goldberg, M.D., Member of Scientific Advisory Board, Annexon, said that the inhibition of C1q could offer neuroprotective gain by avoiding the unusual loss of functioning synapses that damages the retina.

Goldberg added that there is a substantial requirement to advance novel neuroprotective therapies which can reduce the damage to the optic nerve, avoiding the chance of vision loss in patients suffering from Glaucoma or any other ophthalmic diseases.

As for Sanjay Keswani, Chief Medical Officer, Annexon, the company is delighted with ANX007’s safety and tolerability. Moreover, based on this positive data, the company’s preclinical data and understanding of C1q biology will tremendously benefit ANX007, taking it to the advanced later-stage clinical studies for many ophthalmic diseases such as geographic atrophy.

Annexon has also made some significant advancement last year when it announced that it had secured $75 million from its Series C funding round, that was led by Bain Capital Life Sciences.

Sources cite that the funding saw active participation from new and existing investors, such as Blackstone Life Sciences, NEA, Satter Investment Management and Novartis Venture Fund and was pivotal for the advancement of the Annexon’s clinical trials.

Source Credit: https://www.annexonbio.com/news/october-9-2019/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...